Stock Events

Stock Events

Oncopeptides AB 

€0.12
0
-€0-3.85% Today

Statistics

Day High
0.13
Day Low
0.12
52W High
0.56
52W Low
0.12
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
-0.02
0.32
0.65
0.98
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OND.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol-Myers Squibb competes in the oncology space with a broad portfolio of drugs that could be used in similar indications as Oncopeptides' therapies.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its subsidiary Janssen, develops multiple myeloma treatments that directly compete with Oncopeptides' products.
AMGEN
AMGN
Mkt Cap185.74B
Amgen has a strong presence in the oncology market, including treatments for multiple myeloma, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, with its acquisition of Kite Pharma, has expanded its oncology portfolio, including therapies that could compete in the same space as Oncopeptides.
Novartis
NVS
Mkt Cap280.79B
Novartis offers several cancer treatments, including therapies for multiple myeloma, positioning it as a competitor.
Pfizer
PFE
Mkt Cap153.59B
Pfizer has a growing oncology division with treatments that could compete against Oncopeptides' pipeline.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie, with its broad oncology portfolio, including therapies for hematologic cancers, competes in the same market as Oncopeptides.
Merck
MRK
Mkt Cap276.38B
Merck & Co.'s strong oncology pipeline, including treatments for various cancers, makes it a competitor.
Takeda Pharmaceutical
TAK
Mkt Cap52.54B
Takeda Pharmaceutical, with its acquisition of Shire, has strengthened its position in the oncology market, including treatments for multiple myeloma, competing with Oncopeptides.

About

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Ms. Sofia Heigis M.Sc.
Employees
80
Country
United States
ISIN
SE0009414576

Listings

STU
DE
OND.STU
MU
DE
OND.MU
ST
SE
ONCO.ST
LSE
GB
0RN4.LSE

0 Comments

Share your thoughts

FAQ

What is Oncopeptides AB stock price today?▼
The current price of OND.STU is €0.12 EUR — it has decreased by -3.85% in the past 24 hours. Watch Oncopeptides AB stock price performance more closely on the chart.
What is Oncopeptides AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncopeptides AB stocks are traded under the ticker OND.STU.
Is Oncopeptides AB stock price growing?▼
OND.STU stock has risen by +0.93% compared to the previous week, the month change is a -2.29% fall, over the last year Oncopeptides AB has showed a -31.77% decrease.
When is the next Oncopeptides AB earnings date?▼
Oncopeptides AB is going to release the next earnings report on May 13, 2026.
How many employees does Oncopeptides AB have?▼
As of April 29, 2026, the company has 80 employees.
In which sector is Oncopeptides AB located?▼
Oncopeptides AB operates in the Health & Wellness sector.
When did Oncopeptides AB complete a stock split?▼
Oncopeptides AB has not had any recent stock splits.
Where is Oncopeptides AB headquartered?▼
Oncopeptides AB is headquartered in Stockholm, United States.